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Hepatitis C virus (HCV) infects chronically 3% of the
world population and the current therapy against
this pathogen is only partially effective. With the
aim of developing novel antiviral strategies against
HCV, we screened a D,L-a-peptide library using
an unbiased methodology based on a cell culture
infection system for HCV. We found a family of
highly active amphiphilic eight-residue cyclic D,L-
a-peptides that specifically blocked entry of all
tested HCV genotypes into target cells at a postbind-
ing step without affecting infection by other envel-
oped RNA viruses. Structure-activity relationship
studies indicate that antiviral activity was dependent
on cyclic D,L-a-peptide self-assembly processes
and that, although they possess a net neutral
charge, they display a characteristic charge distribu-
tion. Our results indicate that supramolecular amphi-
philic peptide structures constitute a class of highly
selective HCV entry inhibitors.
INTRODUCTION
The hepatitis C virus (HCV) is an enveloped member of the Flavi-
viridae family with a 9.6 kb positive stranded RNA genome that
causes acute and chronic hepatitis and hepatocellular carci-
noma (Hoofnagle, 2002; Liang et al., 2000). More than 170million
people are chronically infected with this blood-borne pathogen
worldwide (Alter, 1997) making HCV a major worldwide killer
and themost common cause of liver transplantation in theUnited
States (Alter, 1999). Despite the fact that new therapies based on
combinations of interferon with direct-acting antivirals (DAAs)
have improved the proportion of responding patients, the
concern for rapid emergence of resistant variants fuels the
search for new antivirals targeting different aspects of the viral
lifecycle that could be used in combination therapies (Gelman
and Glenn, 2010).
HCV infection is initiated by binding of the viral particle to
cellular receptors at the surface of the target cell (reviewed in
Burlone and Budkowska [2009]). Subsequently, internalizationChemistry & Biology 18, 1453–146of the bound virus particles through receptor-mediated endocy-
tosis (Blanchard et al., 2006) results in the fusion of viral and
cellular membranes triggered by endosome acidification
(Tscherne et al., 2006), delivery of the viral genome to the
cytosol, and primary translation of the incoming HCV genome
by a process that is dependent on the cellular autophagy
machinery (Dreux et al., 2009). The HCV genome encodes
a single polyprotein that is co- and posttranslationally cleaved
by cellular and viral proteases into structural (core, E1, E2, and
p7) and nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and
NS5B) proteins (Bartenschlager and Lohmann, 2000) that
mediate viral genome replication and progeny virus assembly
and secretion (reviewed in Moradpour et al., 2007 and Murray
et al., 2008) by a process that exploits the cellular lipoprotein
biosynthetic machinery (Chang et al., 2007; Gastaminza et al.,
2008; Huang et al., 2007; Jiang and Luo, 2009; Kapadia and
Chisari, 2005; Su et al., 2002; Ye et al., 2003).
Until recently, the lack of cell culture and small animal infection
systems limited analysis of HCV infection to surrogate models,
e.g., autonomously self-replicating viral RNAs (replicons) (Blight
et al., 2000; Lohmann et al., 1999) and pseudotyped virus parti-
cles (Bartosch et al., 2003) that reproduced only selected
aspects of the virus life-cycle (Hao et al., 2007; Kim et al.,
2007). With the advent of cell culture models of HCV infection
in human hepatoma-derived cell lines based on the genotype
2a JFH-1 strain of HCV (Lindenbach et al., 2005; Wakita et al.,
2005; Zhong et al., 2005), the entire viral lifecycle became
accessible in cell culture, thus providing the opportunity to study
the impact of known and novel antiviral compounds on all
aspects of the viral lifecycle. We recently developed a miniatur-
ized colorimetric system that permits efficient analysis of HCV
infection, replication, assembly, secretion, and spread in cell
culture (Gastaminza et al., 2010). We adapted this methodology
to screen a library of 144 pre-selected nontoxic, amphipathic,
membrane-active cyclic D,L-a-peptides (Fernandez-Lopez
et al., 2001) for antiviral activity against the parental JFH-1
HCV strain.
Self-assembling peptide nanotubes are a versatile class of
supramolecular structures with expanding utility in materials
and biological settings. Cyclic peptides made up of an even
number of alternating D- and L-a-amino acid residues adopt
(or sample) flat ring-shaped conformations in which all amide
backbone functionalities reside approximately perpendicular to2, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1453
Table 1. Peptide Sequences of Hits from Primary Library Screening and Peptide 9 Derivatives Used in the SAR Studies
Name Sequence EC50 (mM) LD50 (mM) Net Charge
Primary hits 1 c[w-L-w-S-e-Q-s-K] 3.3 ± 0.5 65 0
2 c[w-L-w-S-e-K-n-S] 7.7 ± 3.8 >100 0
3 c[w-L-w-S-s-K-e-N] 7.9 ± 2.1 >100 0
4 c[w-L-w-S-e-Q-s-O] 10.3 ± 3.4 >100 0
5 c[w-L-w-R-e-Q-e-R] 15.5 ± 2.8 >100 0
6 c[w-L-y-K-r-E-d-Y] 8.9 ± 1.6 >100 0
7 c[w-L-w-Z-e-Q-e-Z] 6.9 ± 3.4 80 0
8 c[w-L-w-R-e-S-q-K] 3.4 ± 0.4 90 1
9 c[w-L-w-O-e-N-e-K] 11 ± 2.8 >100 0
SAR (peptide 9 derivatives) 10 c[w-L-w-E-o-N-k-E] >50 >100 0
11 c[w-L-w-S-e-N-s-K] 6.5 ± 0.8 >100 0
12 c[w-L-w-O-s-N-e-S] 7.8 ± 0.3 >100 0
13 c[W-l-W-o-E-n-E-k] 5.5 ± 1.2 45 0
14 c[w-L-w-E-o-N-e-K] 18.4 ± 3.6 >100 0
15 Ac-w-L-w-O-e-N-e-K-NH2 >50 nd 0
16 Ac-N-e-K-w-L-w-O-e-NH2 >50 nd 0
17 Ac-L-w-O-e-N-e-K-w-NH2 >50 nd 0
18 c[w-LMe-w-S-e-N-sMe-K] >50 nd 0
19 c[w-LMe-w-SMe-e-N-s-K] >50 nd 0
Primary hits and derivatives of peptide 9 were generated as described in the text and assayed for their antiviral activity (EC50) and toxicity (LD50) as
shown. EC50 values were determined by colorimetric evaluation of HCV infection in the presence of increasing peptide concentrations (0.75–
50 mM). LD50 values were determined by monitoring parallel cultures for cell viability using the XTT assay (see Experimental Procedures). Values
are shown as average andmean error of aminimumof three experiments. Net chargewas estimated by the charge of the individual amino acids. Amino
acids shown in lower case represent D-configuration. Ac, acetyl group; Me, N- methylation; nd, not determined; SAR, structure-activity relationship;
Z, 2,3-diaminopropionic acid. See also Tables S1 and S2.
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Anti-HCV Peptide Nanotubesthe plane of the ring structure (Ghadiri et al., 1993, 1995; Hartger-
ink et al., 1996; Kobayashi et al., 1995). In this conformation,
because of the spatial disposition and juxtaposition of amide
hydrogen-bond donor and acceptor sites on either side of the
ring structure, the peptide subunits can stack under conditions
that favor hydrogen bonding, such as lipid membranes, to form
uniformly shaped and contiguously hydrogen-bonded b sheet
like tubular ensembles (Clark et al., 1998; Ghadiri et al., 1994;
Granja and Ghadiri, 1994; Kim et al., 1998). We have shown
that appropriately designed amphiphilic cyclic D,L-a-peptides
are able to selectively target and self assemble in bacterial
membranes and exert antibacterial activity by increasing the
membrane permeability (Dartois et al., 2005; Fernandez-Lopez
et al., 2001; Fletcher et al., 2007). Furthermore, using adenovirus
as a model nonenveloped virus, we previously identified antiviral
cyclic D,L-a-peptides that specifically prevented the develop-
ment of low pH in endocytic vesicles, thereby arresting the
escape of virions from the endosome and abrogating adenovirus
infection without adversely affecting cell viability (Horne et al.,
2005). Due to their abiotic backbone structures, these peptides
are both chemically and proteolytically stable and can be tar-
geted to operate in a variety of settings and environments. In
the present work, we report the discovery of a family of, to our
knowledge, novel HCV-specific antiviral molecules. We demon-
strate that these peptides operate by preventing viral entry and
require a cyclic configuration and the ability to self-assemble
as nanotubes to exert their antiviral activity.1454 Chemistry & Biology 18, 1453–1462, November 23, 2011 ª2011RESULTS
Identification of a Family of HCV Inhibitors
Over the past few years we have amassed a collection of >1200
eight-residue cyclic D,L-a-peptides in pure forms that were
derived from various libraries designed to probe the sequence-
space for effective antimicrobial agents (Dartois et al., 2005;
Fernandez-Lopez et al., 2001; Horne et al., 2005; Motiei et al.,
2009; Wilcoxen, 2002). From this peptide depository, which
represents a small sampling of a rather diverse cyclic D,L-
a-peptide sequence-space, a panel of 144 sequences known
to be nontoxic in HeLa cells (LD50 > 100 mM) was screened for
antiviral activity against HCV (see Table S1 available online) in
a cell-based ELISA assay that integrates the number of infected
cells and the amount of viral antigen per cell in a 96-well format
(Gastaminza et al., 2010). This screen yielded nine cyclic amphi-
philic octapeptides (Table 1) that were characterized by a neutral
charge, the presence of either Ser or positively charged residues
adjacent to the hydrophobic region of the molecule, and
predominantly Glu, Asp, or Gln residues at the remaining posi-
tions. All the peptides identified by the counterscreen displayed
an EC50 between 8 to 16 mM and the virtual absence of toxicity
(R100 mM in Huh-7 cells).
To ascertain the mode of antiviral action of this peptide family,
we treated the target cells with the peptides at different times
relative to the time of inoculation with the virus (Figure 1). This
analysis showed that the peptides displayed an antiviral effectElsevier Ltd All rights reserved
Figure 1. Time of Addition Studies Reveal Inhibition of Early Steps of
HCV Infection with D,L-a-Peptides
Peptides (20 mM) were added to target cells 5 hr prior to inoculation (cell
pretreatment), during the 5 hr (37C) inoculation period (cotreatment), after
virus infection (treatment postinfection), or were present at all times (present
all-time). Infection efficiency was measured by colorimetry 72 hr postinfection
as described in Experimental Procedures. Results are shown as average and
mean error of two independent infections. See also Figure S1.
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Anti-HCV Peptide Nanotubeswhen the peptide was present during the initial inoculation period
(5 hr) or throughout the experiment, but not if they were preincu-
batedwith the cells for 5 hr before virus inoculation or if they were
added to the cells 5 hr after inoculation, i.e., after infection was
complete. These results suggested that the peptides interfered
with an early step of the infection, such as steps involved in viral
entry. Another possibility was that the peptides reduced the
infectivity of the viral particles by directly interacting with and/or
destabilizing them, as was recently described for a linear
amphiphilic anti-HCV peptide (Cheng et al., 2008). To test that
hypothesis, we incubated the virus with the peptides (20 mM)
for 5 hr at 37C, after which viral infectivity was determined by
dilution of the virus-peptide mixture to a final peptide concentra-
tion at least 50-fold below the EC50. As shown in Figure S1, the
peptides did not notably reduce the infectivity or the amount of
viral RNA in the inoculum, suggesting that the peptides are not
virocidal. This finding is particularly important because the anti-
viral peptides are capable of interactingwith lipidmembranes, as
measured by dye release assays in unilamellar vesicles (Table
S2). This property, however, did not correlate with the antiviral
activity of the peptides, indicating that liposome lysis capacity
is not sufficient for the observed anti-HCV activity. Collectively,
these results imply that the peptides target an early step in the
HCV infection cycle and likely share a common mode of action.
Structural Features Required for Antiviral Activity
(Structure-Activity Relationship Analysis)
To probe the features required for antiviral activity, we modified
the amino acid sequence of a representative member of the
amphiphilic cyclic D,L-a-peptide family (peptide 9) in a manner
that would preserve its overall neutral charge. To test whether
one or more acidic residues can be tolerated at positions next
to the hydrophobic domain, compounds 10 and 14were synthe-
sized and tested for antiviral activity. Reversing the amino acid
positions of Lys/Orn and Glu pairs to place one or two negatively
charged Glu residues at the hydrophobic interface in cyclicChemistry & Biology 18, 1453–146peptides 10 and 14 led to either complete or significant loss of
antiviral activity, respectively (Table 1). Interestingly, despite
lack of antiviral activity of peptide 10, this compound was found
to be membranolytic in liposome dye release assays (Table S2),
reinforcing the notion that membrane activity is not sufficient for
antiviral activity. The above data thus suggest that, in addition to
the amphiphilic net neutral charge structure, the amino acid
sequence is also a strong determinant of antiviral activity.
In order to probe the influence of Lys/Orn and Glu pairs on
antiviral activity, we synthesized net neutral peptides 11 and 12
in which a Lys/Orn and a Glu residue were simultaneously
replaced with Ser residues. These derivatives displayed slightly
increased potency (EC50 of 6.5 mM for 11 and 7.5 mM for 12;
Table 1) in line with the level of activities observed for similar
sequences (peptides 1, 2, and 3; Table 1), suggesting that
placing a Ser residue at the hydrophobic/hydrophilic interface
can have a positive influence on the antiviral activity.
By virtue of their flat ring structure and special backbone
amide bond disposition, cyclic D,L-a-peptides have a propensity
to undergo intermolecular hydrogen-bond-directed self-
assembly into nanotubular assemblies. Previous studies in the
design and discovery of antimicrobial cyclic D,L-a-peptides
have strongly correlated peptide self-assembly and antimicro-
bial activity (Fernandez-Lopez et al., 2001). Similarly, in this study
we examined whether the cyclic structure and supramolecular
assembly are also required for the antiviral activity of the anti-
HCV peptides. Accordingly, acetylated linear versions of proto-
typic peptide 9were synthesized and tested against HCV. These
linearized sequences (peptides 15, 16, and 17; Table 1) failed to
block HCV infection, establishing that a cyclic structure is
required for potency. To establish whether peptide self-
assembly is also required for the observed antiviral activity,
backboneN-methylated analogs of peptide 11were synthesized
(compounds 18 and 19). Specific backbone N-alkylation of
cyclic D,L-a-peptides has been shown to limit peptide self-
assembly to only dimeric structures (Bong et al., 2001; Ghadiri
et al., 1993, 1994). As shown in Table 1, backbone N-alkylation
resulted in complete loss of activity. Another line of support for
the supramolecular nature of the active species is that
compound 13, the enantiomeric version of 9, was also active in
blocking HCV infections. Overall, the above studies support
the notion that a mechanistic requirement for these cyclic D,L-
a-peptides to reduce HCV infection is their self-assembly into
supramolecular species.
Having identified the major structural determinants of this
group of antiviral molecules, we next set out to gain insights
into the mode of action by defining at which step of the viral life-
cycle thesemolecules impede HCV infection. To accomplish this
goal, we used the most potent and least toxic peptides from the
above studies (peptides 9, 11, and 12) in the following studies.
Mechanism of Action
The time-of-addition experiments suggested that these peptides
target early steps in the viral lifecycle. To test this hypothesis, we
performed single-step infection experiments in which Huh-7
cells were inoculated with a high virus dose (multiplicity of infec-
tion [moi] of 5) for 5 hr in the presence of the indicated peptides
(20 mM), after which the cells were extensively washed and incu-
bated with fresh complete medium for an additional 24 hr. As2, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1455
Figure 2. D,L-a-Peptides Inhibit Infection in a Postbinding Step
Preceding Viral RNA Replication
(A) Single cycle infection in the presence of antiviral peptides. Huh-7 cells were
inoculated at multiplicity of 5 (moi 5) with HCV for 5 hr at 37C in the presence
of vehicle (DMSO) or the designated peptide (20 mM). After the inoculation
period, the cells were washed once with PBS and further incubated in
complete medium without peptides. Infectivity was determined in total cell
extracts and supernatants 24 hr postinoculation. Left: intracellular infectivity
(FFU/ml). Right: extracellular infectivity (FFU/ml). Data are shown as average
and mean error of duplicate infections. *Peptide 4 not shown, tested under
same conditions displayed inconsistent results.
(B) D,L-a-peptides do not display anti-HCV activity in the replicon model.
Huh-7 cells harboring a full-length JFH-1 replicon were treated with cyclic
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1456 Chemistry & Biology 18, 1453–1462, November 23, 2011 ª2011shown in Figure 2A, the peptides inhibited intracellular and extra-
cellular virus particle production in this experiment, confirming
that they indeed interfere at an early step in HCV infection.
To determine if peptide 9 and its derivatives inhibit HCV RNA
replication, we incubated Huh-7 cells harboring a full-length
JFH-1 replicon with the peptides (20 mM) or dimethyl sulfoxide
(DMSO) and measured the intracellular HCV RNA content 48 hr
later. Parallel cultures were incubated with the HCV protease
inhibitor BILN2061 (1 mM) (Lamarre et al., 2003) or polymerase
inhibitor 20-C-methylcytidine (2-CMC) (1 mM) (Carroll and Olsen,
2006) as a control. As shown in Figure 2B, BILN2061 and 2-CMC
efficiently reduced HCV RNA levels whereas peptide 9 and its
derivatives did not. These results suggest that the peptides
target events upstream of replication, probably at the level of
viral entry. These findings also confirm the observation that the
peptides do not show any antiviral activity when added after
the virus had entered the cell in the time-of-addition experiment
(Figure 1).
To determine if the peptides inhibit a binding or post-binding
step in viral entry, we temporally separated these two events
by inoculating the target cells at 4C to allow virus particle
binding while minimizing internalization (Koutsoudakis et al.,
2006; Tscherne et al., 2006). Huh-7 cells were inoculated for
1 hr at 4C in the presence or absence of peptides 9, 11, and
12 (20 mM) after which the cells were washed twice with ice-
cold PBS and replenished with warm medium to promote viral
internalization (Tscherne et al., 2006). Cultures were then incu-
bated for 72 hr at 37C and the viral titer was determined as
described in Zhong et al. (2005). As shown in Figure 2C, the
inhibitory peptides did not alter the binding of the virus to the
target cell, reinforcing the notion that they are not virocidal, as
shown in Figure S1, and suggesting that they inhibit an event
downstream of binding. To test this hypothesis directly, Huh-7
cells were inoculated at low temperature after which unbound
virus was removed by extensive washing with cold PBS and
bound virus internalization was triggered by addition of warm
medium containing the antiviral peptides (20 mM). After a 5 hr
incubation at 37C, medium containing the peptides was
removed and the cells were replenished with complete medium
lacking the peptides after extensive washing with PBS. Cultures
were incubated for an additional 72 hr after which infection effi-
ciency was evaluated by immunofluorescence. Treatment of
Huh-7 cells with the antiviral peptides during viral internalization
resulted in profound inhibition of viral infection (Figure 2C), sug-
gesting that the antiviral peptides inhibit a step in viral entry
downstream of cell binding.peptide (20 mM), the protease inhibitor BILN2061 (1 mM), or the polymerase
inhibitor 20-C-methyl-cytidine (1 mM) for 48 hr at 37C. Intracellular HCV RNA
levels were determined by RT-qPCR and normalized with GAPDH mRNA
levels. Results are shown as average and mean error of triplicate experiments.
(C) D,L-a-peptides do not interfere with infectious particle binding but target
a post-binding step of the viral lifecycle. Huh-7 cells were inoculated with
increasing amounts of infectious HCV for 1 hr at 4C in the presence of
a constant amount of peptide (20 mM). Susceptibility of binding or post-binding
events to inhibition was studied by adding the peptide during inoculation or
after virus particle binding to target cells (see Experimental Procedures).
Infection efficiency was calculated by determining the infectivity titer in each
condition and comparing it with that obtained in the presence of vehicle
(DMSO).
Elsevier Ltd All rights reserved
Figure 3. HCV-Pseudotyped Lentiviral Particles Are Susceptible to
the Antiviral Action of D,L-a-Peptides
(A) Serial dilutions of the peptides were mixed with constant amounts of HCV-
pseudotypes and used to inoculate Huh-7 cells.
(B) HCV and VSV-G pseudotype infections were carried out in parallel in the
presence of peptide (20 mM) to assess the specificity of inhibition. Infection
efficiency in the presence of the peptides was estimated by reporter gene
expression (luciferase) and compared to that obtained in the control (DMSO).
Relative luciferase activity values are shown as average and mean error of
triplicate infections.
Figure 4. D,L-a-Peptides Inhibit All Tested HCV Genotypes
Supernatants containing infectious HCV particles from genotypes 1a, 1b, or 2a
were serially diluted in complete medium containing the indicated antiviral
peptides (20 mM) and used to inoculate naive Huh-7 cells. Seventy-two hours
postinoculation, cells were fixed and processed for immunofluorescence to
determine viral infectivity titer. Data are shown as average and mean error of
duplicate infections.
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Anti-HCV Peptide NanotubesTo further confirm these findings, we studied the ability of
increasing concentrations of peptides 9–12 to inhibit entry of
HCV-pseudotyped lentiviral particles (HCVpp) into Huh-7 cells
(Hsu et al., 2003). As shown in Figure 3A, HCV-pseudotyped
lentiviral particle entry was efficiently inhibited in a dose-depen-
dent manner by peptides 11 and 12 but not 10, confirming that
these molecules inhibit HCV entry. Interestingly, lentiviral parti-
cles bearing VSV glycoprotein (VSVpp) were not susceptible to
inhibition by the same peptide concentrations, (Figure 3B) sug-
gesting that the peptides display selective antiviral activity
against HCV in a process mediated by the viral glycoprotein
complex.
Antiviral Spectrum and Specificity
To determine the antiviral spectrum of these molecules against
different HCV genotypes, we tested their efficacy against parti-Chemistry & Biology 18, 1453–146cles bearing structural proteins from JFH-1 and J6CF (2a),
H77 (1a) and Con1 (1b). Serial dilutions of infectious HCV parti-
cles corresponding to the different genotypes were used to inoc-
ulate Huh-7 cells in the presence of 20 mM of the most potent
peptides (compounds 11 and 12), as well as in the presence of
peptide 10 (Figure 4), which was shown to have no effect on
JFH-1 virus infection (Table 1). Remarkably, compounds 11
and 12 strongly inhibited HCV infection by particles bearing
structural proteins from genotypes 1a, 1b, and 2a, as shown in
Figure 4, suggesting that they are active against all the tested
HCV genotypes.
To determine if the antiviral effect of the peptides is limited to
HCV, we asked if compounds 10–12 (20 mM) could inhibit the
entry of influenza A (Flu A), VSV, or LCMV. Interestingly, in
contrast to HCV, none of these viruses was susceptible to the
antiviral action of the selected peptides (Figure 5), suggesting
that they have a selective effect against HCV.
Efficient Control of Viral Spread
Having shown that these peptides interfere with viral entry in
a single infection cycle (Figure 2A), we sought to determine if
they could also restrict viral spread during multiple rounds of
infection. Thus, we infected Huh-7 cells with infectious virus at
low multiplicity (moi 0.01 ffu per cell) in the presence of the
most active antiviral peptides (compounds 11 and 12; 20 mM).
Four days postinoculation, we observed that, as expected,2, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1457
Figure 5. D,L-a-Peptides Are Specific for HCV and Do Not Interfere
with Infection by Other Enveloped RNA Viruses
Dilutions of the selected antiviral peptides (20 mM) or the endosome acidifi-
cation inhibitor chloroquine (20 mM) were mixed with supernatants containing
infectious HCV, influenza virus, VSV, and LCMV. Relative infectivity titers
were determined as described in Experimental Procedures and shown in each
case (A–D) as average and mean error of duplicate experiments. Values are
expressed as percentage relative to the control.
Figure 6. Efficient Control of Viral Spread by Selected D,L-
a-Peptides
Huh-7 cells were infected at low multiplicity (moi of 0.01) and incubated for the
designated periods of time in the presence of 20 mM of the antiviral peptides.
Cells were replenished with fresh medium containing the peptides at days 4
and 8 postinfection.
(A) HCV-infected cells are revealed by immunofluorescence microscopy with
antibodies against the viral protein E2and are shown in red (E2). Cell nuclei of
infected and uninfected cells were stained with Hoescht dye and are shown in
blue (nuclei).
(B) Intracellular HCV RNA accumulation was measured by RT-qPCR at the
indicated time points. Results are shown as average and mean error of tripli-
cate samples.
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expressed viral envelope protein (E2) as revealed by immunoflu-
orescence microscopy (Figure 6A, DMSO day 4; red cells).
However, the virus was capable of efficiently spreading to almost
all the DMSO-treated cells, as shown by the large proportion of
HCV-antigen positive cells observed at day 12 postinfection (Fig-
ure 6A, DMSO day 12; red cells). However, the virus infected and
spread inefficiently or did not spread at all in cells treated with
peptide 11 or peptide 12 respectively, as shown by the virtual
absence of HCV-positive cells at day 12 postinfection in the
peptide-treated cells (Figure 6A; peptide 11 and 12) and the
greatly reduced accumulation of viral RNA in the cultures over
time (Figure 6B). These results suggest that these antiviral
peptides can efficiently control viral spread in cell culture even
if they are only replenished every 4 days.
DISCUSSION
In this study, we discovered a family of net-charge neutral
peptides that inhibit HCV infection at a postbinding step during
viral entry by screening a small library of amphiphilic eight-
residue cyclic D,L-a-peptides. Chemical and structural modifi-1458 Chemistry & Biology 18, 1453–1462, November 23, 2011 ª2011cations to a representative member of the family, and analysis
of the antiviral activity of the resulting derivatives, revealed
some of the key requirements for the observed anti-HCV activity.
A characteristic pattern of acidic and basic amino acids in
the peptide sequence, a cyclic backbone configuration, and
the ability for the peptide to undergo self-assembly were all
necessary for anti-HCV activity. Together, these results strongly
suggest a supramolecular nanotubular nature of the active
species (Table 1).
Time-of-addition experiments suggested that early events
in the viral lifecycle are targeted by the peptides (Figure 1).
The lack of inhibitory effect on HCV replicons (Figure 2B)Elsevier Ltd All rights reserved
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inhibited by the peptides, whereas cold-inoculation studies
(Figure 2C) suggested that the peptides inhibit a post-binding
step during viral entry into the target cell. Furthermore, these
compounds showed comparable potency (EC50) against HCV-
pseudotyped lentiviral particles (Figure 3A), further suggesting
that viral entry is targeted by the peptides. In contrast, VSV-
pseudotyped lentiviral particle entry was not inhibited by the
peptides (Figure 3B), suggesting that they are targeting a mech-
anism that is unique to HCV and is probably mediated by the
envelope glycoproteins. This was confirmed by the lack of
susceptibility of other enveloped RNA viruses (Influenza, VSV,
and LCMV) to inhibition by the peptides (Figure 5).
The amphiphilic nature of these peptides and their known
ability to interact with and self-assemble in synthetic lipid
membranes (Table S2) suggest that their site of action is most
likely either the viral envelope or cellular membranes (Fernan-
dez-Lopez et al., 2001) (Horne et al., 2005). We have shown
that the intrinsic infectivity of the particles is not altered after
incubation with the antiviral peptides, so we therefore hypothe-
size that they exert their antiviral activity by interacting with
specialized cellular membranes. It is also important to note
that although membrane activity seems to be required, it is not
sufficient for anti-HCV activity, because we have shown that
peptide 10, a related membrane-active peptide (Table S2),
does not inhibit HCV entry. Therefore, in addition to the apparent
requirement for amphiphilic cyclic D,L-a-peptide structure
that enables membrane interaction and potential self-assembly
into self-assembling nanotubular species, the observed level of
sequence specificity seems to be the key for HCV-selective
activity and the low apparent toxicity. The cellular receptors
that mediate HCV entry have been shown to localize in specific
areas of the plasma membrane (Voisset et al., 2008). Therefore,
it is tempting to speculate that the differential composition of
these plasma membrane domains through which HCV pene-
trates the cells forms the basis of the specificity of the peptides.
Further studies will be required to determine the exact biochem-
ical and biophysical mechanisms underlying inhibition of
HCV infection by amphiphilic cyclic D,L-a-peptide structures.
Remarkably, the polymeric amphipathic nature of these inhibi-
tory peptides evokes the amphipathic DNA polymers shown
to inhibit HCV infection at a similar post-binding entry step
(Matsumura et al., 2009), or the previously described small
molecule LJ001 that specifically intercalates into a broad-spec-
trum of viral membranes, inhibiting entry of the virus at a step
after virus binding but before virus-cell fusion (Wolf et al.,
2010). Whether the molecular mechanism underlying these inhi-
bitions is similar remains to be determined.
Finally, compounds that efficiently inhibit viral spread, like the
peptides presented in this study, can complement the antiviral
activity of other compounds, as part of a combination therapy.
Such combination therapies could lessen the likelihood of the
emergence of resistant variants by reducing their spread to other
cells.
SIGNIFICANCE
The Hepatitis C virus is comprised of multiple genotypes,
and significant heterogeneity exists even within genotypeChemistry & Biology 18, 1453–146subgroups. Moreover, emergence of drug-resistant quasis-
pecies is a major issue, and combinatorial drug therapy
targeting different aspects of the viral lifecycle is required
for sustained efficacy. Therefore, there is an urgent need
for new classes of anti-HCV drugs. To our knowledge, this
study presents a new class of supramolecular agents
specifically targeting HCV entry at a post-binding step. Our
results suggest that these antiviral peptides can efficiently
control viral spread in cell culture, making them potential
candidates for controlling spread of the infection in vivo,
including restricting the spread of emerging drug-resistant
virus variants in combination therapy. It is noteworthy that,
based on our previous studies, membrane-selective self-
assembling cyclic D,L-a-peptides can be derived from a
vast sequence space, so there is considerable room for
further structure-activity optimizations.Moreover, as a class
of bioactive supramolecular species, cyclic D,L-a-peptides
are in general stable to proteolysis and have proven in vivo
utility and antimicrobial efficacy. Therefore, it seems likely
that the basic findings described here could catalyze the
development of practical therapeutic applications.EXPERIMENTAL PROCEDURES
Peptide Chemistry
Synthesis of the Cyclic Peptides
Linear peptides were synthesized using standard Fmoc solid phase synthesis
protocols, manually or with an Advanced Chemtech Peptide Synthesizer
Model 348 U. A typical synthesis was performed on 0.07 mmol scale using
0.8–1.0 mmol/g 2-chlorotrityl resin for preparation of Fmoc-aa-(OAll)-chlorotri-
tyl resin. Chain elongations were achieved using DIC and HOBt in NMP with
coupling reaction times ranging from 4 to 12 hr either manually or 65 min
when using the peptide synthesizer. Fmoc deprotection was achieved using
20% piperidine in NMP (2 3 15 min). The allyl deprotection step was carried
out manually after swelling of the resin in dry DCM for 20 min. To the resin
was added a degassed solution of 0.5 eq Pd(PPh3)4 in DCM followed by
10 eq phenylsilane. After shaking under nitrogen for 2 hr, the resin was washed
sequentially with DMF, DCM, and DMF. Resin was treated again for 2 hr with
0.5 eq Pd(PPh3)4 DCM and phenylsilane under nitrogen and washed with
a solution of 1% sodium dimethylthiocarbamate in DMF and 1% DIEA in
DMF. After the final Fmoc deprotection, subsequent cyclization was achieved
using HATU as coupling agent in the presence of DIEA in NMP. Peptides
were cleaved from the resin with concomitant side chain deprotection by
agitation in a solution of 95:2.5:2.5 trifluoroacetic acid (TFA)/H2O/triethylsilane
(TES) for 2 hr. The crude peptide was precipitated with ether, centrifuged, and




Huh-7 cells were cultured as previously described (Zhong et al., 2005). JFH-1
virus was generated by transfection and viral stocks were produced by infec-
tion of Huh-7 cells at a moi of 0.01 as described (Zhong et al., 2005). At day
8–10 postinoculation, supernatants were collected and the infectivity titer
was determined as described below. High titer stocks of D183 virus (Zhong
et al., 2006) were prepared by infection of a Huh-7.5.1 cells at low multiplicity
(moi of 0.01) as described (Zhong et al., 2005). Generation of recombinant
chimeric HCV viruses (J6CF, H77, and Con1-JFH-1) chimeric HCV genomes
described (Pietschmann et al., 2006) was previously described.
Influenza A virus (A/WSN/33) was kindly provided by Dr. Adolfo Garcı´a-
Sastre (Mount Sinai School of Medicine-New York, NY). Lymphocytic chorio-
meningitis virus (LCMV/Armstrong) was kindly provided by Dr. Juan Carlos De
La Torre (The Scripps Research Institute). Vesicular stomatitis virus (Indiana)
was acquired from ATCC.2, November 23, 2011 ª2011 Elsevier Ltd All rights reserved 1459
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HCV. Infectivity titers were determined on Huh-7 cells by end point dilution
and immunofluorescence as previously described (Zhong et al., 2005). Typi-
cally, 25 ml of each sample were serially diluted 5-fold in D-MEM 10% FCS
and 100 ml were used to inoculate Huh-7 cells. Infection was examined 72 hr
postinoculation by immunofluorescence using a 1:1000 dilution of a recombi-
nant monoclonal human IgG anti-E2 (C1 antibody, a gift from Dr. Dennis
Burton, The Scripps Research Institute) with the appropriate secondary
Alexa555-conjugated antibodies. For analysis of antiviral activity, an HCV
focus reduction assay was performed as described (Cheng et al., 2008).
Briefly, the peptideswere reconstituted in 100%DMSOat a final concentration
of 10 mM and stored at –20C. A virus-peptide mixture containing 50–75 FFU
and 20 mMof peptide was prepared in complete medium (D-MEM + 10% FCS)
and used to inoculate Huh-7 cells plated (104 cells per well in a 96-well plate,
seeded the day before). The cells were incubated at 37C for 3 days after which
the cells were immunostained as described above. The number of HCV-
positive foci was counted by fluorescence microscopy and expressed as
a percentage of the number of control foci in cells incubated with a virus-
DMSOmixture. Infectivity of intracellular virions was determined by four cycles
of freezing-thawing of infected cell suspensions as previously described
(Gastaminza et al., 2006).
LCMV. Different dilutions of LCMV were used to inoculate Huh-7 cells for
1 hr at 37C. The cells where washed and replenished with complete medium.
Infectivity was measured 20 hr post-infection by immunofluorescence as
described above for HCV using a specific antibody against LCMV NP (NP
1.1.3, a gift from Dr. Juan Carlos De La Torre, The Scripps Research Institute).
LCMV ‘‘focus reduction assay’’ was performed identically to that of HCV using
a specific antibody against LCMV NP (see above), except for a different
incubation period postinoculation of 20 hr.
Influenza. Increasing dilutions of influenza A virus (A/WSN/33) were used to
inoculate Vero cells for 1 hr at 37C. Cells were washed and replenished
with complete medium (D-MEM + 10% FCS). Infectivity was measured 72 hr
postinfection by endpoint dilution. Influenza infectivity reduction assays
were performed by endpoint dilution titration in the presence of 20 mMpeptide.
The inoculum was removed 2 hr postinoculation and noninternalized virus was
inactivated by washing the cells with an acid PBS buffer (pH 5.2). The cells
were washed again with PBS and replenished with DMEM + 10% FCS and
incubated for 72 hr. Infectivity titer was determined as described above.
In all of the foregoing experiments, chloroquine (25 mM) was included as
positive control because it has been shown to interfere with endosomal acid-
ification, a process required for internalization of HCV, Influenza, and LCMV
(reviewed in Smith and Helenius [2004]).
Peptide Library Screening
The methodology employed to screen the peptide library was adapted from
that described in Gastaminza et al. (2010, 2011). The modified procedure
involves using the parental JFH-1 strain (Kato et al., 2001) instead of the cell
culture-adapted D183 virus (Zhong et al., 2006) and the Huh-7 cell line instead
of the hyper permissive cell clone Huh-7.5.1.c2 cells (Pedersen et al., 2007).
Peptide stock solutions (10mM) were diluted to the desired final concentration
of 20 mM in D-MEM (10% FCS) growth medium containing 500 focus-forming
units FFU of JFH-1 per well. This mixture was used to inoculate 104 Huh-7
cells/well in a 96-well format. The cells were incubated at 37C for 3 days after
which the cells were fixed with 4% paraformaldehyde. Infection efficiency
was evaluated by colorimetry in a cell-based ELISA-type assay using a
recombinant monoclonal antibody against the viral envelope as described in
Gastaminza et al. (2010).
Discrimination of false positives was carried out by determining the cell
biomass in the control and experimental wells by staining with crystal as
described (Bernhardt et al., 1992), and discarding compounds that reduce
the biomass of the control wells by >25%.
Determination of Potency (EC50) and Toxicity (LD50)
Serial dilutions of the compound were prepared in 9% sucrose solutions using
a Tecan 550 Genesis Pipetting Robot. These solutions (20 ml) were mixed with
80 ml of a virus dilution in complete medium containing 500 FFU leading to final
compound concentrations of 50, 40, 35, 30, 25, 20, 15, 10, 5, 2.5, 1, and
0.1 mM. The mixture was transferred into a 96-well plate containing 1041460 Chemistry & Biology 18, 1453–1462, November 23, 2011 ª2011Huh-7 cells plated the day prior to the experiment The cultures were then incu-
bated for a period of 72 hr at 37C, after which the cells are fixed and pro-
cessed for colorimetry as described above. OD650 values were transformed
using a standard curve as described above and the HCV infection values
relative to the vehicle control were used to calculate EC50 values by interpola-
tion of the 50% in the linear portion of the inhibition curve. LD50 values were
determined by evaluating cell viability using the XTT-formazan method at
different times posttreatment, 24 and 120 hr (Roehm et al., 1991).
Time-of-Addition Assay
Peptides were added at a final concentration of 20 mM under the following
conditions: (1), preinoculation: peptide was added to cells for 5 hr at 37C
followed by washing once with PBS medium before virus infection; (2), coino-
culation: peptide was added to cells together with virus for 5 hr at which
time the cells were washed as above and replenished with complete media
without peptide; and (3), postinoculation: cells were infected for 5 hr at which
point the virus was removed, the cells were washed once with PBS and the
peptide was added and left on the cells for the duration of the experiment
without washing. These conditions were compared with the infection where
the peptides where present at all times. Cells were fixed and processed for
colorimetric analysis 72 hr postinfection as described above.
HCV Pseudotype Particle Infectivity Inhibition Assay
HCV (H77 genotype 1a strain) E1/E2-pseudotyped (or VSV-G pseudotyped as
a control) lentiviral particles bearing the luciferase reporter gene were gener-
ated as described (Flint et al., 2004). For the inhibition assays, equal amounts
of infectious particles were mixed with serial dilutions of the cyclic peptides or
the vehicle (DMSO). The mixture was used to inoculate Huh-7 cells that were
incubated in complete medium for another 72 hr period after which infection
efficiency was evaluated by measuring reporter gene (luciferase) activity in
total cell extracts (Hsu et al., 2003). Relative luciferase activity values were
obtained using untreated cells as control (100%) after background (uninfected
cells) substraction.
Inhibition of Viral Entry: Binding and Postbinding Events
In order to discriminate inhibition of particle binding and postbinding events,
we incubated prechilled target cells (Huh-7) for 1 hr on ice in the presence of
the inhibitors (20 mM). After this adsorption period, cells were washed twice
with cold PBS and replenished with warm D-MEM 10% FCS and incubated
for 72 hr at 37C before infection was revealed by immunostaining.
Parallel cultures inoculated with virus on ice in the absence of peptides (1 hr),
werewashed twicewith cold PBS and replenishedwith D-MEM10%FCScon-
taining candidate peptides (20 mM). Cultures were incubated for 5 hr at 37C
to allow virus internalization after which the cells were washed twice with
PBS and incubated in D-MEM 10% FCS for an additional 72 hr. Infection
efficiency was revealed by immunostaining as described above.
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